Susquehanna International Group
BCLI

Susquehanna International Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Susquehanna International Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,770
Closed -$13.3K – 12040
2024
Q1 		$15K Buy
1,770
+115
+7% +$632 ﹤0.01% 11866
2023
Q4 		$6.78K Buy
+1,655
New +$4.96K ﹤0.01% 12108
2023
Q3 		– Sell
-33,720
Closed -$767K – 12010
2023
Q2 		$1.04M Buy
33,720
+6,936
+26% +$287K ﹤0.01% 6572
2023
Q1 		$1.33M Buy
26,784
+19,713
+279% +$572K ﹤0.01% 6103
2022
Q4 		$174K Buy
+7,071
New +$264K ﹤0.01% 10313
2022
Q3 		– Sell
-1,022
Closed -$51.3K – 13152
2022
Q2 		$42K Sell
1,022
-5,285
-84% -$238K ﹤0.01% 12066
2022
Q1 		$318K Buy
+6,307
New +$310K ﹤0.01% 10129
2021
Q4 		– Sell
-2,602
Closed -$128K – 13101
2021
Q3 		$129K Buy
+2,602
New +$137K ﹤0.01% 11899
2021
Q2 		– Sell
-18,968
Closed -$1.01M – 12543
2021
Q1 		$1.09M Sell
18,968
-5,742
-23% -$434K ﹤0.01% 7510
2020
Q4 		$1.68M Buy
+24,710
New +$3.37M ﹤0.01% 5488
2020
Q1 		– Sell
-4,354
Closed -$340K – 10218
2019
Q4 		$280K Sell
4,354
-2,200
-34% -$128K ﹤0.01% 8160
2019
Q3 		$383K Buy
6,554
+1,147
+21% +$67.7K ﹤0.01% 7831
2019
Q2 		$320K Buy
5,407
+2,073
+62% +$121K ﹤0.01% 8179
2019
Q1 		$217K Buy
3,334
+1,465
+78% +$83.3K ﹤0.01% 7759
2018
Q4 		$100K Buy
1,869
+584
+45% +$28.8K ﹤0.01% 8224
2018
Q3 		$74K Buy
1,285
+508
+65% +$30.7K ﹤0.01% 8713
2018
Q2 		$45K Buy
+777
New +$45.7K ﹤0.01% 9302
2018
Q1 		– Sell
-3,575
Closed -$210K – 9303
2017
Q4 		$210K Buy
3,575
+1,182
+49% +$70.7K ﹤0.01% 8201
2017
Q3 		$148K Buy
+2,393
New +$155K ﹤0.01% 8203
2016
Q4 		– Sell
-1,427
Closed -$51K – 9557
2016
Q3 		$51K Buy
+1,427
New +$53.4K ﹤0.01% 8118
2016
Q2 		– Sell
-1,249
Closed -$50K – 8527
2016
Q1 		$50K Buy
+1,249
New +$45.9K ﹤0.01% 8665

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's BCLI Position: Q2 2024 in Review

Susquehanna International Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2024, closing a stake of 1,770 shares — an estimated $13.3K sold.

Susquehanna International Group first reported a position in BCLI in Q1 2016 and held it in 21 quarters. The position peaked at $1.68M in Q4 2020. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2024.

  • Susquehanna International Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 1,770 BRAINSTORM CELL THERAPUTC shares in Q2 2024, an estimated $13.3K.
  • Susquehanna International Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 21 quarters.
  • Susquehanna International Group's BRAINSTORM CELL THERAPUTC position peaked at $1.68M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.